Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia - sprookjes - yvandenbroek - TriplyDB

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

http://www.wikidata.org/entity/Q24594920

about

In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors Clinical development of gene therapy: results and lessons from recent successes Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy Current clinical immunotherapeutic approaches for head and neck cancer Immunotherapy for head and neck cancer: latest developments and clinical potential Natural Killer Cells for Therapy of Leukemia Clinical manufacturing of CAR T cells: foundation of a promising therapy Role of the tumor microenvironment in mature B-cell lymphoid malignancies CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy Chronic lymphocytic leukemia: a clinical review including Korean cohorts Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Novel immunotherapies in lymphoid malignancies Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy Cancer-treatment-induced neurotoxicity--focus on newer treatments Adoptive T-Cell Immunotherapy Lymphoma Immunotherapy: Current Status Trial Watch: Adoptive cell transfer for oncological indications Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia T-Cell Therapy: Options for Infectious Diseases Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Immune Modulation in Hematologic Malignancies Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street Current practices and reform proposals for the regulation of advanced medicinal products in Canada The past, present and future of immunotherapy against tumor Adoptive T-cell therapy for cancer: The era of engineered T cells CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma CAR T Cell Therapy: A Game Changer in Cancer Treatment B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look CAR T cells for solid tumors: armed and ready to go?T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect

P2860

Q21559398-A1842805-9C44-40CF-A88E-C1C9754BD4B7 Q24632975-B48383B5-343E-48C8-98B7-28883A9E352A Q26741260-CC2A5D13-B7C8-4E43-9670-551A73C58A1A Q26743393-D2EDF419-AD8F-45C6-8B73-CEE9C684E92F Q26744654-5B6BFC36-795E-4F7C-8FD6-0E73685A0B09 Q26745411-6BC61F9A-06D0-4E79-A66C-731B9EB05565 Q26745428-9CA903A3-D337-48FF-A03F-76C249D80CC1 Q26745906-72F0BE7F-0418-4ED7-8248-40E32ED8C690 Q26747037-AD45A0B5-7519-4F00-9B24-C64EAE63E47F Q26748775-1943991C-6A3E-440D-9022-07FFFA4C0038 Q26749139-651B59B9-49F6-4C10-BEA3-B580E7CAE75E Q26749560-8784CDCD-7060-4287-961B-80AE3EA7A665 Q26752467-77790839-D570-4742-872F-B2FC463A2D41 Q26765115-67486061-6002-4E38-BCF5-F2F87A64A47C Q26770391-D0DD733F-0FB5-455E-9D62-EC32E40D8CA4 Q26771192-228BA4AF-1A79-4760-AF34-C5682AC09251 Q26773309-23DC79E9-740E-4EBE-BFDA-D01FD8282C0F Q26775720-7F75116E-3524-41D3-913D-E8E1D54B2C0D Q26777394-37B4DAFF-8E0B-47D2-8496-27AD7246F7FC Q26779221-6FE25014-EA0C-457D-B65D-C5425235FFC1 Q26779938-677D8328-2CD9-4CBF-82D4-2A45F63BCEF4 Q26782604-A8A7DF63-F0E6-43CE-A537-A7D840B06FBE Q26782845-48E2D142-C9FE-4F98-AADF-63ECFFDE5770 Q26782902-4E22407B-833D-49FD-A0B0-BE6F600D5D10 Q26785545-8AF1DF7D-7BBC-4AA6-9CA1-605C0CBA6AA7 Q26785828-815FC7DB-235B-4E36-8524-29D7C208E3C6 Q26786661-1CDA18D0-607A-4DCB-B65A-228DA31FBCFB Q26795540-2FD60646-5F76-411A-A703-963D1932751C Q26796307-B836C391-3ECA-4537-BCBF-518146C8F70C Q26798062-C8C7C976-A8BB-49BF-AD3F-982814F27016 Q26798404-9769E2E2-1679-41DC-9A69-8AFBBDD2009A Q26799357-5F9B3F58-F9AD-4787-A0B6-31A490E43BAF Q26799720-A087E787-9247-49B2-B9EA-F504C618FF99 Q26799896-AAF5BCB1-C8E5-4895-9583-6B7AEF6989C3 Q26800611-B5F485D4-241A-4854-81BC-E79535F865D1 Q26800814-34118C3C-2B9B-442B-9A4D-F0299BD686CF Q26822769-D85B14B4-5524-4F6D-8E44-7136832458C5 Q26824446-FE8FEA28-0EF2-4A1F-AD80-0B3F81E15162 Q26825489-2E1CECF2-5E03-4B6F-A041-C32CA35361D3 Q26826830-8BFAA239-A4C5-4BA2-B338-833427745661

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

http://www.wikidata.org/entity/Q24594920

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@ast

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@en

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@nl

type

label

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@ast

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@en

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@nl

prefLabel

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@ast

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@en

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@nl

P1433

Q24594920-3CF976B4-C083-4152-A9BD-BED3A80B1DA9

P1476

Q24594920-FA1976CC-EA50-48B6-9E42-76E3A8D31FF9

P2093

Q24594920-1D12846A-B79B-402C-8E2A-FE27B98DB69A

Q24594920-201DC497-2481-4CF5-AD57-AE455AD07B74

Q24594920-6FF8CCCE-C214-4840-BEFB-C4DCD6A154EB

Q24594920-ACD8444F-CFCE-4686-96C1-A87B22B2B131

Q24594920-D1E460E8-5F5E-460F-AD76-B24B7AB3FF18

P2860

Q24594920-18150D07-E585-4908-A664-B6E79E918880

Q24594920-1A063855-7318-4DFD-852D-15324B679D9A

Q24594920-20F439D2-A53D-492C-95A6-C98F15F49C59

Q24594920-421E46F4-8ECC-461B-8F29-F8C1004AEE07

Q24594920-4A1CDC20-566D-46C2-933D-05306F516304

Q24594920-50435693-F361-47B0-B8A9-F01A84A0391D

Q24594920-59710CE0-2D16-49FC-B18E-DFA4872CD867

Q24594920-628DD4E5-7A0C-403B-996A-64D776CC6EE5

Q24594920-833E87D0-89C8-4E0D-AE14-2EA559917E3E

Q24594920-8F5AA938-4259-4969-9558-AE82458A3249

P304

Q24594920-9C5A9801-B9DE-4D43-AB24-9AA39011CB85

P31

Q24594920-552A5F9D-1216-4F3F-979D-2F5019B35F66

P3181

Q24594920-4D653F20-DA49-40C2-9146-458AE88B8A61

P356

Q24594920-0EDCBB19-6539-4FD4-9AD4-400F64636845

P407

Q24594920-3BC190CF-B880-416D-9973-6EBBFB925F59

P433

Q24594920-B08B7406-CF3D-45BE-A347-1646FEAFFF3A

P478

Q24594920-DD9737C4-CE0D-4D64-9D88-EA221E9ED1D1

P5008

Q24594920-49D880E0-2B40-458F-89AB-0E892427E1E9

P577

Q24594920-F4AD0CEA-33F2-4AB2-ABE0-DE7E263A4AA3

P698

Q24594920-D4662FEB-9779-4806-A43E-FAB4837F926D

P921

Q24594920-108803a1-4179-c0b0-526c-215917078f3b

Q24594920-3194D0C7-6545-48F1-BE52-4D25C0EAD40E

P932

Q24594920-1D4417AE-84F0-4A5C-BF1A-46C85ED29CE3

P3181

P356

P1433

The New England Journal of Medicine

P1476

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

@en

P2093

Adam Bagg

http://www.w3.org/2001/XMLSchema#string

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

David L Porter

http://www.w3.org/2001/XMLSchema#string

Michael Kalos

http://www.w3.org/2001/XMLSchema#string

P2860

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

The promise and potential pitfalls of chimeric antigen receptors.

Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.

P304

725-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

759426

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1103849

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2011-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21830940

http://www.w3.org/2001/XMLSchema#string

P921

lymphoid leukemia

P932

3387277

http://www.w3.org/2001/XMLSchema#string